TORRENT PHARMA LTD

TORRENT PHARMA LTD

TORRENT PHARMA LTD - Company Information

Print Friendly Version

TORRENT PHARMA LTD

Company Registration Number:
NI602282 (Northern Ireland)

Unaudited abridged accounts for the year ended 28 February 2021

Period of accounts

Start date: 29 February 2020

End date: 28 February 2021

TORRENT PHARMA LTD

Contents of the Financial Statements

for the Period Ended 28 February 2021

Balance sheet
Notes

TORRENT PHARMA LTD

Balance sheet

As at 28 February 2021


Notes
2021
2020


£
£
Fixed assets
Intangible assets: 3 310,800 310,800
Tangible assets: 4 14,357 14,357
Total fixed assets: 325,157 325,157
Current assets
Stocks: 41,200 41,200
Debtors:   66,796 66,796
Cash at bank and in hand: 43,797 43,797
Total current assets: 151,793 151,793
Creditors: amounts falling due within one year:   (448,436) (448,436)
Net current assets (liabilities): (296,643) (296,643)
Total assets less current liabilities: 28,514 28,514
Creditors: amounts falling due after more than one year:   (1,677) (1,677)
Provision for liabilities: (2,727) (2,727)
Total net assets (liabilities): 24,110 24,110
Capital and reserves
Called up share capital: 2 2
Profit and loss account: 24,108 24,108
Shareholders funds: 24,110 24,110

The notes form part of these financial statements

TORRENT PHARMA LTD

Balance sheet statements

For the year ending 28 February 2021 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 05 May 2022
and signed on behalf of the board by:

Name: Denver Devlin
Status: Director

The notes form part of these financial statements

TORRENT PHARMA LTD

Notes to the Financial Statements

for the Period Ended 28 February 2021

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

TORRENT PHARMA LTD

Notes to the Financial Statements

for the Period Ended 28 February 2021

2. Employees

2021 2020
Average number of employees during the period 6 6

TORRENT PHARMA LTD

Notes to the Financial Statements

for the Period Ended 28 February 2021

3. Intangible Assets

Total
Cost £
At 29 February 2020 776,870
At 28 February 2021 776,870
Amortisation
At 29 February 2020 466,070
At 28 February 2021 466,070
Net book value
At 28 February 2021 310,800
At 28 February 2020 310,800

TORRENT PHARMA LTD

Notes to the Financial Statements

for the Period Ended 28 February 2021

4. Tangible Assets

Total
Cost £
At 29 February 2020 54,979
At 28 February 2021 54,979
Depreciation
At 29 February 2020 40,622
At 28 February 2021 40,622
Net book value
At 28 February 2021 14,357
At 28 February 2020 14,357